共 26 条
[1]
Weidinger S(2018)Atopic dermatitis Nat Rev Dis Primers 4 1-437
[2]
Beck LA(2017)Commonality of the IL-4/IL-13 pathway in atopic diseases Expert Rev Clin Immunol 13 425-1204
[3]
Bieber T(2020)Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4Rα antibody, is required to broadly inhibit type 2 inflammation Allergy 75 1188-1101
[4]
Kabashima K(2018)Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ) Br J Dermatol 178 1083-2303
[5]
Irvine AD(2017)Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Lancet 389 2287-2348
[6]
Gandhi NA(2016)Two phase 3 trials of dupilumab versus placebo in atopic dermatitis N Engl J Med 375 2335-895
[7]
Pirozzi G(2021)What are the best endpoints for eczema area and severity index and scoring atopic dermatitis in clinical practice? A prospective observational study Br J Dermatol 184 888-79
[8]
Graham NMH(2016)Report from the fourth international consensus meeting to harmonize core outcome measures for atopic eczema/dermatitis clinical trials (HOME initiative) Br J Dermatol 175 69-undefined
[9]
Le Floc'h A(undefined)undefined undefined undefined undefined-undefined
[10]
Allinne J(undefined)undefined undefined undefined undefined-undefined